Digital chronic disease management platform Health2Sync has recently raised $20 million in a Series C funding round led by Taiwania Capital. Wistron, Pegatron, BE Health Ventures, ABIES Capital, and Cathay Venture also joined the round.
This latest investment brings its total capital raised since its founding in 2013 to over $30 million.
WHAT IT'S FOR
In a media release, the company said it...
Western Sydney Diabetes has rolled out a mobile diabetes management application from Taiwan as part of its patient engagement digitisation.
A centre led by the Western Sydney Local Health District (WSLHD), WSD has established an automated patient engagement programme with Health2Sync. It features the Health2Sync app which provides personalised lifestyle suggestions on managing blood sugar levels...
South Korea clears Coreline Soft's AI brain haemorrhage detection software
An AI-powered brain haemorrhage detection software by medtech company Coreline Soft is now listed as a non-insured medical device in South Korea following its approval from the Ministry of Food and Drug Safety.
The software product called AVIEW Neuro CAD automatically detects cerebral haemorrhages in brain CT scans and...
French multinational pharmaceutical and healthcare company Sanofi announced a partnership with New York-based TrialSpark, which offers a technology-based model for drug development.
TrialSpark's tools aim for more efficient trial design, faster trial completion and higher quality trial data. It acquires clinical-stage drugs from pharmaceutical and biotech companies and develops them using its...
Digital chronic disease management platform Health2Sync has signed a memorandum of understanding with pharmaceutical firm AstraZeneca to launch a digital patient management programme for patients with chronic kidney disease.
The digital programme seeks to promote the early diagnosis of CKD and optimise everyday CKD care using Health2Sync's patient management platform.
According to a media release...
Taiwan-based digital health startup Health2Sync and French multinational pharmaceutical firm Sanofi have signed another partnership to bring digital solutions for insulin management to Japan.
WHAT IT'S ABOUT
According to a press statement, both companies will jointly develop digitised features on insulin in Japan, including connected caps for insulin and titration alerts.
Health2Sync has a mobile...
Taiwanese chronic disease management company Health2Sync has entered into a partnership with Danish pharmaceutical firm Novo Nordisk to help patients undergoing insulin therapy wirelessly transfer dose logs to a mobile health app.
The Health2Sync mobile app is now able to sync patients' dose logs, including time and dosage per injection, from the newly released NovoPen 6 and NovoPen Echo Plus...
Health2Sync, a digital health startup based in Taiwan, and French multinational pharmaceutical firm Sanofi have extended their collaboration to soon come up with and market a new insulin management solution.
WHY IT MATTERS
The companies noted the "suboptimal" use of insulin in Taiwan and Asia. A recent study published in the Journal of Diabetes Investigation shared that approximately half of...
Taiwan-based diabetes management app Health2Sync has launched the latest version of its mobile app for about 200,000 users in Japan that now integrates continuous glucose monitoring data from the Abbott FreeStyle LibreLink mobile app.
WHY IT MATTERS
This data integration, said Health2Sync in a statement, will enable comprehensive health management for people with diabetes. It will allow them to...
Taiwan-based diabetes management app Health2Sync and DAIKYO ASTAGE INCORPORATED, a Japan-based apartment management company, has partnered to provide health management services to residents in DAIKYO ASTAGE managed apartments in Japan.
The partnership also includes two local pharmacies, Primary Pharmacy Co., Ltd. and Yakuju Co., Ltd., and will commence in the city of Kawasaki City, Kanagawa...
![[Left] Ed Deng, co-founder and CEO, Health2Sync; and [Right] Claudio Longo, President, AstraZeneca Taiwan](https://www.mobihealthnews.com/sites/default/files/styles/230x130/public/(Left) Ed Deng%2C Co-founder and CEO of Health2Sync and (Right) Claudio Longo%2C President of AstraZeneca Taiwan.jpg?itok=O1YqUgdy)
